Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call

Author's Avatar
Oct 23, 2019
Article's Main Image

TAVALISSE® net product sales increased 15% quarter over quarter to $11.7 million

Positive results from IRAK1/4 Proof-of-Mechanism study in humans

Announced new RIP1 inhibitor program, lead molecule enters Phase 1 clinical trial

Appoints Wolfgang Dummer, MD, PhD as Chief Medical Officer

Investor/analyst conference call and webcast today at 10:00am Eastern Time

PR Newswire